Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5050MR)

This product GTTS-WQ5050MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Heloderma suspectum
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5050MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1636MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-910
GTTS-WQ7503MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ4153MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ1309MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ4916MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ349MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ11795MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ3669MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1213790
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW